Acute effects of coffee and major coffee components on glucagon-like peptide 1 response and glucose tolerance in humans

• Conditions: diabetes; impaired glucose tolerance; 10018424

• Registration Number: NL-OMON31301
• Lead Sponsor: Vrije Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 20

Inclusion Criteria

- Apparently healthy males as assessed by the questionnaires during the pre-study visit, and the results of the pre-study clinical laboratory tests and urinalysis
- Age at screening: 18 years and above
- Body mass index (BMI) between 25.0 and 35.0 kg/m2
- Regular coffee consumer (1 cup per day or more)
- Willing to restrict coffee consumption during the study to max. 1 cup per day
- Voluntary participation
- Willing not to be blood or plasmaferese donor from 4 weeks before the start of the study until the end of study

Exclusion Criteria

- Women
- Smokers
- Subjects with diabetes will be excluded (fasting blood glucose >= 7.0 mmol/l or physician-diagnosis of diabetes)
- Blood sampling is considered too difficult (assessed during pre-study screening)
- Any chronic or acute disease (e.g. diabetes, renal disease, inflammation, cardiovascular disease). Therefore the medical questionnaire will be evaluated by a doctor from the research team.
- Hypertension criteria for moderate hypertension WHO 2003: systolic > 140 mmHg or diastolic > 90 mmHg
- Medical history or surgical events known to interfere with the study
- Alcohol consumption > 28 consumptions per week
- Self reported weight loss or gain > 2 kg in the month prior to screening
- Any special diet (prescribed, slimming, macrobiotic or vegan). Sole exclusion of meat and fish from an otherwise *normal* western diet is allowed
- Participation in any other trial up to 3 months before and during this study
- Use of medication known to interfere with the study outcome e.g.: Medication interfering with digestion or glucose metabolism, such as corticosteroids and beta-blockers
- Exercising more than 4 hours vigorously per regular week

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Concentrations of glucose, insulin, glucagon-like peptide 1 secretion, and the<br /><br>activity of dipeptidyl peptidase IV will be measured during 2 hours following<br /><br>an oral glucose tolerance test.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N.A.</p><br>